Quality Control

Before we release the antibody to the market, it first has to pass ELISA titre and specificity tests.

ELISA titre:

The immunizing peptide is coated to the wells of a high bond microtitre plate. Serially diluted antibody is applied from 1:1000 to 1:128000 in steps of factor 2. When no signal above non-specific background is obtained at 1:1000, the antibody is rejected and it will not be released. The lowest dilution with signal above background is presented on the datasheet as the limit dilution (Peptide-ELISA titre). See protocol.

Specificity:

The antibody is tested in relevant tissues or cell lines when available. Some antibodies cannot be tested by ourselves when tissues or cell lines are required that we have no access to, or when there is no sufficient data available in the literature to compare our test results with. In such cases we release the product as Aspiring Grade and sell them at discount until the right scientist is identified to validate the product. A free vial of antibody is made available to the scientist who can test conclusively the product’s specificity and is willing to share the validating data for the product sheet.